| Literature DB >> 34172516 |
Julie R Brahmer1, Hamzah Abu-Sbeih2, Paolo Antonio Ascierto3, Jill Brufsky4, Laura C Cappelli5, Frank B Cortazar6,7, David E Gerber8, Lamya Hamad9, Eric Hansen10, Douglas B Johnson11, Mario E Lacouture12, Gregory A Masters13, Jarushka Naidoo1,14, Michele Nanni10, Miguel-Angel Perales12, Igor Puzanov10, Bianca D Santomasso15, Satish P Shanbhag5,16, Rajeev Sharma10, Dimitra Skondra17, Jeffrey A Sosman18, Michelle Turner1, Marc S Ernstoff19.
Abstract
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: antineoplastic protocols; guidelines as topic; immunotherapy
Mesh：
Substances：
Year: 2021 PMID： 34172516 PMCID： PMC8237720 DOI： 10.1136/jitc-2021-002435
Source DB: PubMed Journal: J Immunother Cancer ISSN： 2051-1426 Impact factor: 13.751